Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefdinir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 0.79 |
| ▸ | APAF1 | O14727 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.79 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.79 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.78 |
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefdinir SCHEMBL3299566 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36995 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL6820723 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL2221924 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL5919457 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL1559599 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36996 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114437 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114446 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137182-A1 | Novel crystalline form of cefdinir | AUROBINDO PHARMA LIMITED (IN) | 2005-06-23 | — | — | US | claimed |
| US-20040242556-A1 | Novel crystalline form of cefdinir | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | claimed |
| EP-1392703-B1 | CRYSTALLINE ACID SALTS OF CEFDINIR AND PROCESS FOR PREPARING CEFDINIR USING SAME | HANMI SCIENCE CO LTD (KR) | 2014-09-03 | — | — | EP | disclosed |
| US-7741478-B2 | Salts in the preparation of cephalosporin antibiotics | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-06-22 | — | — | US | disclosed |
| US-20080306256-A1 | Salts in the Preparation of Cephalosporin Antibiodies | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20070191602-A1 | Crystalline form of cefdinir cesium salt | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-08-16 | — | — | US | disclosed |
| US-7244842-B2 | Amorphous hydrate of a cephalosporin antibiotic | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2007-07-17 | — | — | US | disclosed |
| EP-1765833-A2 | NEWS SALTS IN THE PREPARATION OF CEPHALOSPORIN ANTIBIOTICS | Orchid Chemicals and Pharmaceuticals Limited (IN) | 2007-03-28 | — | — | EP | disclosed |
| US-7157576-B2 | Crystalline acid salts of cefdinir and process for preparing cefdinir using same | HANMI PHARM. CO., LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-7105659-B2 | Process for preparing cefdinir | AUROBIND - PHARMA LTD. (IN) | 2006-09-12 | — | — | US | disclosed |
| US-20060094703-A1 | Novel amorphous hydrate of a cephalosporin antibiotic | ORCHID CHEMICALS AND PHARMACEUTICALS LTD. (IN) | 2006-05-04 | — | — | US | disclosed |
| US-20040242557-A1 | Process for preparing cefdinir | AUROBINDO PHARMA LTD. (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-1392703-A4 | CRYSTALLINE ACID SALTS OF CEFDINIR AND PROCESS FOR PREPARING CEFDINIR USING SAME | HANMI PHARM IND CO LTD (KR) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004046154-A1 | NOVEL AMORPHOUS HYDRATE OF A CEPHALOSPORIN ANTIBIOTIC | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-06-03 | — | — | WO | disclosed |
| EP-1392703-A1 | CRYSTALLINE ACID SALTS OF CEFDINIR AND PROCESS FOR PREPARING CEFDINIR USING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098884-A1 | CRYSTALLINE ACID SALTS OF CEFDINIR AND PROCESS FOR PREPARING CEFDINIR USING SAME | HANMI PHARM. CO., LTD. (KR) | 2002-12-12 | — | — | WO | disclosed |
| EP-0874853-B1 | PROCESS FOR PREPARATION OF CEFDINIR | HANMI PHARMACEUTICAL CO LTD (KR) | 2002-06-05 | — | — | EP | disclosed |
| US-6093814-A | A VERY PURE, CRYSTALLINE INTERMEDIATE BY REACTING A 2-ETHYLENE-6-AMINO-3-CEPHEM WITH A TRITYL-PROTECTED REACTIVE ESTER OF AN (2-AMINOTHIAZOL-4-YL)-,Z-CARBONYL-OXIME USING DIMETHYLACETAMIDE AND TOLUENESULFONIC ACID; DEPROTECTION | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2000-07-25 | — | — | US | disclosed |
| EP-0874853-A1 | PROCESS FOR PREPARATION OF CEFDINIR | HANMI PHARMACEUTICAL CO.,LTD. (KR) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024358-A1 | PROCESS FOR PREPARATION OF CEFDINIR | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242557-A1 | Process for preparing cefdinir | ACMSD, DCXR, AADAT | TDP1 4789/4885MAPT 4225/4885ABCC4 2564/4885 |
| US-20070191602-A1 | Crystalline form of cefdinir cesium salt | RCSD1, CHLSN, CES1 | TDP1 4681/4885MAPT 1335/4885ABCC4 1263/4885 |
| US-20080306256-A1 | Salts in the Preparation of Cephalosporin Antibiodies | ABCB11, SLC10A1, NISCH | TDP1 4358/4885MAPT 3770/4885ABCC4 178/4885 |
| US-20040242556-A1 | Novel crystalline form of cefdinir | VSIR, CYP2C9, DCXR | TDP1 4831/4885MAPT 965/4885ABCC4 695/4885 |
| US-20050137182-A1 | Novel crystalline form of cefdinir | VSIR, CYP2C9, CYP8B1 | TDP1 4810/4885MAPT 1238/4885ABCC4 550/4885 |
| US-20060094703-A1 | Novel amorphous hydrate of a cephalosporin antibiotic | C1R, CEP170, Q6ZSR9 | TDP1 3355/4885MAPT 1249/4885ABCC4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.